Beyond the Knife: How GLP1s, Targeted Chemo, and Adjuvant Therapies are Cutting Into Reconstructive Approaches and Outcomes Thursday, October 9 Thu, Oct 9 1:30-3:00 p.m. CDT

This innovative panel explores the evolving landscape of reconstructive plastic surgery in the context of modern pharmacological advances. As GLP-1 inhibitors dramatically alter body composition, chemotherapeutic agents continue to evolve, and new adjuvant therapies emerge, plastic surgeons face novel challenges and opportunities in patient care. Expert panelists will discuss how these medical developments impact surgical planning, technique selection, timing of interventions, and long-term outcomes. Through case presentations and interactive discussion, participants will gain practical insights into integrating these considerations into their reconstructive practice to optimize patient results in this rapidly changing environment.

Upon completion of this learning activity, participants should be able to:

1. Identify how GLP-1 inhibitors affect tissue characteristics, body composition, and wound healing relevant to reconstructive plastic surgery procedures
2. Describe the impact of modern chemotherapeutic agents on timing considerations, flap selection, and postoperative care in oncologic reconstruction
3. Evaluate how adjuvant therapies influence preoperative planning and intraoperative decision-making in various reconstructive scenarios
4. Implement evidence-based strategies to optimize outcomes in patients concurrently using these pharmacological treatments
5. Anticipate and address potential complications unique to patients on these therapeutic regimens